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Several monocyte/macrophage-derived factors have been reported to influ-
ence human and murine B cell function. Interleukin 1 (IL-1), a product of
activated monocytes, has been shown (1, 2) to augment both the proliferation
and differentiation of human B cells. Additionally, stimulated monocytes have
been shown (3) to release a factor that induces the differentiation of antigen-
activated murine B cells to Ig secretion. Such a monocyte-derived B cell differ-
entiation factor (BCDF) has been reported to be functionally identical to a factor
that also triggered the selective differentiation of murine B cells and was present
in the serum of LPS-treated Bacillus Calmette-Guerin (BCG)-infected mice (3,
4).
Besides this BCDF activity, the serum of such treated mice has been found (5)
to cause hemorrhagic necrosis and regression of certain tumors in mice. The
factor responsible for this activity has been termed tumor necrosis factor a (TNF-
a) . Subsequently, TNF-a has been found to be a product of activated monocytes
and it has been purified, sequenced, and cloned by recombinant DNA techniques
(6-8). Purified and recombinant TNF-a is cytotoxic or cytostatic against a variety
of tumor cell lines.
The availability of recombinant TNF-a has allowed us to directly test whether
this cytokine modulates human B cell function .
Materials and Methods
Cell Preparation.
￿
B cell-enriched populations were obtained from tonsillar mononu-
clear cells as previously described (1). These preparations of B cells were routinely >95%
surface immunoglobulin (slg)-positive, <1% esterase positive, and <1% OKT3* (Ortho
Pharmaceutical Corp., Raritan, NJ) as determined by immunofluorescence and esterase
staining.
Factors. Recombinant IL-1-,B was purchased from Genzyme Corporation (Boston,
MA). Recombinant IL-2 (lot LP2) was kindly provided by the Cetus Corporation (Emer-
yville, CA). TNF-a (lot TD4) was also kindly provided by Cetus Corp. and contained a
bioactivity of 1 .3 x 10' U/mg, an endotoxin level of 0.089 ng/mg, and was >95% pure
by SDS-PAGE. Recombinant IFN--y was kindly provided by Genentech Corporation
(South San Francisco, CA). B cell growth factor (BCGF), lot number 15117, was purchased
from Cellular Products, Inc. (Buffalo, NY).
Culture Condition and Assays.
￿
Purified B cells were cultured in RPMI 1640 supple-
mented with 10% FCS (Dutchland Laboratories, Inc., Denver, PA) and gentamicin (50
,ug/ml) in 75 cm' culture flasks (Costar Data Packaging, Cambridge, MA) at a concentra-
tion of 10' cells/ml with a 1 :20,000 vol/vol dilution of Staphylococcus aureus Cowan (SAC)
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FIGURE 1 .
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(A) Dose response to TNF-a. Purified tonsillar B lymphocytes were cultured for
2 d in the presence of SAC in medium containing 10% FCS. The cells were harvested, washed,
and recultured in serum-free media with varying concentrations of TNF-a. ['H]Thymidine
incorporation was measured 3 d later. (B) TNF-a costimulates with anti-ju. Purified tonsillar B
lymphocytes were cultured in the presence of media alone, 15 ug/ml of rabbit anti-human
IgM coupled to beads, 10% BCGF, 40 ng/ml of TNF-a, anti-,u plus BCGF, or anti-ju plus TNF-
a. ['H]Thymidine incorporation was measured during the last 18 h of a 72-h culture. Data
represents the mean ± SEM of two experiments.
strain I (Bethesda Research Laboratories, Bethesda, MD). Because we found that serum-
containing media often suppressed the subsequent response of in vitro-activated B cells
to IL-2, TNF, and BCGF (our unpublished observation), on the second day of culture the
cells were harvested, washed twice with RPMI 1640, and recultured in Ventrex HL-1
serum-free media (Ventrex Laboratories, Inc., Portland, ME) at a concentration of 5 x
105 cells/ml in 96-well Costar plates in the presence or absence of various cytokines. The
culture was continued for the indicated time periods, and DNA synthesis was measured
during the last 18 h of the culture period by the incorporation of ['H]thymidine using
standard liquid scintillation counting techniques. The anti-ju costimulation assay was
performed as previously described (1). IgG and IgM levels in culture supernatants were
measured by an isotype-specific ELISA.
Receptor Studies.
￿
Purified recombinant TNF-a (10 jug) was radiolabelled using iodo-
beads (Pierce Chemical Co., Rockford, IL) and separated from free iodide by filtration
over a Sephadex G-25 column. The radiolabelled TNF had a s?ecific activity of 5.7
mCi/mg and was biologically active when assayed on L929 cells.
12 I-TNF radioreceptor
binding assays were performed by suspended 106 B cells in 100 pl of binding buffer
(Ventrex media plus 25 mM Hepes) and incubating them with increasing amounts of 125I-
TNF in the presence or absence of a 500 molar excess of unlabelled TNF. After 2 h of
binding at 23°C with agitation, cell associated and free 1251-TNF were separated by
overlaying the reaction mixture on a cushion of 84% silicon oil (Dexter Hysol, Olean,
NY) and 16% paraffin oil (Fischer Scientific, Fair Lawn, NJ) and centrifuging at 12,000
x g for 1 min. The resultant binding data were analyzed by the LIGAND computer
program developed by Munson and Rodbard (9).
TNF-a Maintains the Proliferation ofSAC-activated B Cells and Costimulates with
Anti-,u in the Induction ofB Cell DNA Synthesis. Stimulation of human B lympho-
cytes with the polyclonal B cell activator, SAC, is only sufficient to trigger an
initial round of B cell proliferation. However, in the presence of an appropriate
growth factor such as I L-2 or BCGF, the proliferation is maintained (10, 11).
The effects of various concentrations of TNF-a on the incorporation of [sH]-
thymidine by B cells preactivated with SAC is shown in Fig. 1 A. The addition of788
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FIGURE 2. Effects of TNF-a plus IL-1, IFN-y, BCGF, or IL-2 on B cell proliferation.
Preactivated tonsillar B cells were cultured with varying concentrations of TNF-a in the
presence or absence of the above factors, medium (0), 10 U/ml of IL-1 (A), 100 U/ml of IFN-
y (0), 10% vol/vol of BCGF (V), or 100 U/ml of IL-2 (A). [sH]Thymidine incorporation was
measured 3 d (day 5 of culture) or 5 d later (day 7 of culture).
25 ng/ml of TNF-a to these cultures resulted in a fivefold increase in thymidine
incorporation compared to B cells cultured with media alone. Half-maximal
stimulation occurred at a concentration of 5 ng/ml (285 pM) of TNF-a .
Using an anti-A costimulation assay, we next examined whether TNF-a could
enhance anti-p-triggered B cell proliferation. TNF-a could costimulate with anti-
k in this assay, but not as efficiently as a BCGF preparation (Fig. 1 B).
TNF-a Enhances the Effects of IL-1, IL-2, and IFN-y on SAC-activated B Cell
Proliferation. To test whether TNF-a modulated the effects of factors known
to enhance B cell function (1, 10-12), optimal concentrations of BCGF, IL-1,
IL-2, and IFN-y were added to 2-d SAC-activated B cells in conjunction with
increasing concentrations of TNF-a (Fig. 2). DNA synthesis was measured 3 and
5 d later. TNF-a augmented the B cell proliferation compared to a media control
at both days 5 and 7. The addition of TNF-a to either IL-1 or IFN-y resulted
in a greater increase in DNA synthesis than did either factor alone at both day
5 and day 7. Additionally, TNF-a increased IL-2-induced B cell proliferation at
both days 5 and 7 by 40%, but it did not augment BCGF induced proliferation
at either time . Subsequently, the BCGF preparation was found to contain a
moderate concentration of TNF (data not shown).
TNF-a ItselfDoes Not Induce Ig Secretion by SAC-activated Human B Cells, But It
Can Augment IL-2-induced IgM Secretion of These Cells. Because of the original
report that serum from BCG-infected and LPS-challenged mice, in conjunction_ 4
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FIGURE 3.
￿
TNF-aaugments IL-2 inducedBcell dif-
ferentiation. B cells were activated with SAC for 2 d,
washed, and recultured in serum-free medium in the
presence or absence of 100 U/ml IL-2 with varying
concentrations of TNF-a. Supernatant IgM levels
were measured 7 d later using an ELISA (mean ±
SEM of twoexperiments).
FIGURE 4.
￿
1251-TNF-a binding to unstimulated or SAC
stimulated B cells. Purified tonsillar B cells were cultured
for 48 h in the presence or absence of SAC. Binding
assays were performed as described in Materials and
Methods. (A), binding in the presence of cold TNF-a;
(0), bindingin theabsence ofcold TNF-a.
with antigen, would induce murine B cell Ig secretion (3, 4), we were interested
in examining the effects ofTNF-aon human Bcell differentiation to Ig secretion.
Using B cells preactivated in vitro with SAC, we added various concentrations
of TNF-a to cultures and measured supernatant Ig concentration 5 d later.
TNF-a by itself did not promote preactivated B cells to secrete Ig but it did
enhance (twofold) the IgM production induced by IL-2 (Fig. 3). Of note, the
effects ofTNF-a on IgM production were more pronounced than its effects on
IgG secretion (data not shown).
Expression of TNF-a Receptors on Human B Cells.
￿
To further characterize the
role of TNF-a in B cell function, receptor binding studies with 1251-TNF-a were
performed. Unstimulated B cells had low levels of receptors not quantifiable
using the LIGAND program; however, B cells that were cultured with SAC for
2 d had an average of6,000 receptors per cell, with a Kd of 2.0 X 10-I° M (200
pM) (Fig. 4). A linear Scatchard was found, which suggests a single affinity class
ofreceptors. The binding of TNF-a to SAC-activated B cells was not secondary
to thepresence ofSAC inthe culture, since the additionofSAC to the unactivated
B cells before the binding assay did not alter the results (data not shown).790
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Discussion
TNF-a has been generally defined by its cytotoxic or cytostatic activity against
certain transformed cell lines. However, recently, Sugarman et al. (13) found
that TNF-a actually enhanced the growth of certain normal cell lines. Addition-
ally, Vilcek et al. (9) have noted that the growth ofhuman FS-4 diploidfibroblasts
was stimulated by TNF-a. In the present study we demonstrate that TNF-a can
also significantlyenhance the proliferation ofactivated Bcells. These bifunctional
effects of TNF-a on cell growth, although unusual, are not unique, as several
other growth factors that can provide positive or negative growth signals, such
as transforming growth factor /3, have been identified (15). The growth-promot-
ing effects of TNF-a for normal human B cells gives further credence to the
hypothesis (14) that TNF-a is a growth factor for certain types of normal cells
and that its antiproliferative effects on transformed cells is the result of an
aberrant response to growth stimulation in cells that lack normal growth regu-
latory mechanisms.
Binding studies with radiolabelled TNF-a have been previously performed
using cell lines that are sensitive targets for the cytotoxic effects of TNF.
Tsujimoto et al. (16) examined the binding of "5I-labelled TNF-a to the TNF-
sensitive cell line, L929, and the TNF-resistant cell line, FS-4. Scatchard analysis
ofthe binding data indicated the presence of 2,200 receptors per L929 cell, with
a Kd of 6.1 X 10-'° M, and 7,500 receptors per FS-4 cell, with a Kd of 3.2 X
10-'° M. In this study activated B cells had approximately three times as many
receptors per cell, with a similar affinity as those reported for L929 cells.
Summary
In this study we demonstrate that the monocyte/macrophage product, tumor
necrosis factor a (TNF-a), has significant in vitro effects of B cell function. It
costimulated with anti-A in the induction of B cell DNA synthesis, and it
prolonged the DNA synthesis initiated in B cell cultures stimulated with the
human B cell mitogen, Staphylococcus aureus Cowan strain I (SAC). The addition
of either IL-1 or IFN-y to TNF-a resulted in a substantial further increase in
DNA synthesis. The addition of TNF-a to IL-2, a known inducer of SAG
activated B cell Ig secretion, resulted in a twofold enhancement in the amount
of IL-2 stimulated B cell Ig secretion. Receptor binding studies with 1251-TNF-a
demonstrate a marked increase in TNF-a binding sites after B cell activation
(6,000 sites per cell, with an apparent Kd of2.0 X 10-'° M). Thus, TNF-a may
be an important factor in human B cell function and is likely to interact with
other T cell and monocyte derived cytokines in the regulation of human B cell
proliferation and Ig production.
We thank M. Rust for editorial assistance.
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